Related Experiment Video
Updated: Mar 10, 2026
Mucin Agarose Gel Electrophoresis: Western Blotting for High-molecular-weight Glycoproteins
Published on: June 14, 2016
Lung-Accumulating Mucin 5AC Silencing by Noninflammatory Lipid Nanoparticles for Asthma Treatment
Zhiqiang Zhao1,2,3, Xinzhu Shan2,3, Weixue Wang2,3
1Department of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Abstract:
Overexpression of Mucin 5AC (MUC5AC) drives excessive mucus secretion and respiratory obstruction, contributing to mortality in severe asthma and mucous obstructive lung diseases (MOLDs). While siRNA-mediated silencing of MUC5AC expression represents an effective strategy to treat MOLDs, our investigation reveals that intratracheal administration of FDA-approved lipid nanoparticle (LNP) carriers can paradoxically lead to MUC5AC increases due to inflammatory side effects. To address this challenge, we designed noninflammatory LNPs for asthma treatment by (I) developing ionizable cationic lipids with low immunogenicity, (II) incorporating anti-inflammatory natural compound derivatives into LNPs, and(III) reducing the N/P ratio of LNP formulations. After three rounds of screening-evaluating gene silencing efficiency (in vitro and in vivo), LNP physicochemical properties and biosafety─we identify a lead candidate formulation (Formulation 1) that achieves 85% MUC5AC silencing efficiency in vivo, outperforming the integrin αvβ6 ligand-modified siRNA (69%), and demonstrates notably improved biosafety when compared to SM102 LNPs and MC3 LNPs. In house dust mite (HDM)-induced asthmatic mice, siMuc5ac-LNPs effectively alleviate airway inflammation and obstruction with a sustained preventive effect. Moreover, Formulation 1 effectively suppresses MUC5AC secretion in a Chronic Obstructive Pulmonary Disease (COPD) patient-derived organoid model. Collectively, we develop a clinically translatable, noninflammatory siRNA delivery platform with therapeutic potential for asthma and other MOLDs.
Insights
Researchers developed non-inflammatory lipid nanoparticles (LNPs) to deliver siRNA for treating Mucin 5AC (MUC5AC) related lung diseases. This new LNP formulation effectively silenced MUC5AC, reducing airway inflammation and obstruction in asthma models.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Respiratory Medicine
Background:
- Mucin 5AC (MUC5AC) overexpression causes mucus obstruction in severe asthma and mucous obstructive lung diseases (MOLDs).
- Standard lipid nanoparticles (LNPs) can paradoxically increase MUC5AC due to inflammatory side effects.
- siRNA delivery offers a potential treatment strategy for MOLDs.
Purpose of the Study:
- To design and develop non-inflammatory LNPs for effective siRNA delivery to treat MUC5AC-driven lung diseases.
- To overcome the inflammatory side effects associated with conventional LNP carriers.
- To create a clinically translatable siRNA delivery platform for asthma and MOLDs.
Main Methods:
- Developed ionizable cationic lipids with low immunogenicity and incorporated anti-inflammatory natural compounds into LNPs.
- Optimized LNP formulations by reducing the N/P ratio and screened for gene silencing efficiency, physicochemical properties, and biosafety.
- Utilized in vitro and in vivo models, including house dust mite (HDM)-induced asthmatic mice and COPD patient-derived organoids.
Main Results:
- Identified a lead candidate formulation (Formulation 1) achieving 85% MUC5AC silencing in vivo, surpassing a benchmark siRNA.
- Demonstrated significantly improved biosafety compared to SM102 and MC3 LNPs.
- Showcased effective alleviation of airway inflammation and obstruction in asthmatic mice with sustained preventive effects.
Conclusions:
- Developed a novel, non-inflammatory siRNA delivery platform using optimized LNPs.
- Formulation 1 shows significant therapeutic potential for treating asthma and MOLDs by effectively suppressing MUC5AC.
- The platform is clinically translatable and addresses a critical unmet need in respiratory disease treatment.
More Related Videos
Related Concept Videos
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:20Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
01:17Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
01:20Antiasthma Drugs: Muscarinic Receptor Antagonists
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...